Abcam, ab119150, Recombinant Human TRAP/CD40L protein (Soluble)

Size: 10µg
Recombinant Human TRAP/CD40L protein (Soluble) is a Human Full Length protein, in the 113 to 261 aa range, expressed in Escherichia coli, with >95%, suitable for SDS-PAGE, ELISA, WB, Dot.
Key facts
Purity:>95% SDS-PAGE,
Expression system:Escherichia coli,
Tags:His tag N-Terminus,
Applications:WB, ELISA, Dot, SDS-PAGESee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Biologically active:No,
Accession:P29965,
Animal free:No,
Carrier free:No,
Species:Human,
Storage buffer:pH: 8Constituents: 50% Glycerol (glycerin, glycerine), 0.32% Tris HCl

Properties and Storage Information:
Shipped at conditions-Blue Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
TRAP/CD40L also known as CD154 or CD40 ligand is a type II transmembrane protein with a molecular mass of approximately 39 kDa. CD40L is mainly expressed on the surface of activated T cells. This protein binds to CD40 a significant receptor present on several immune cells including B cells macrophages and dendritic cells. The interaction with CD40 is essential for immune cell activation and development marking CD40L as an important player in adaptive immunity.
Biological function summary
The interaction between CD40L and CD40 triggers cell proliferation differentiation and apoptosis in immune cells. CD40L contributes to the formation of an immunological synapse encompassing its role in T helper cell function. Furthermore CD40L is implicated in the activation of B cells which are necessary for antibody class switching and memory cell generation. Its broad influence shows CD40L's involvement in immune system regulation and response.
Pathways
CD40L is integral to the CD40 signaling pathway which is involved in immune and inflammatory responses. CD40L activates the NF-kB and JNK signaling pathways by engaging with CD40 which then drives the transcription of genes related to immune response. This signaling cascade impacts several other proteins such as TRAF proteins which act as intermediaries in propagating the signal.
CD40L has been linked to immune-related conditions including autoimmune disorders and inflammatory diseases. Elevated CD40L expression is observed in diseases such as systemic lupus erythematosus (SLE) and rheumatoid arthritis. In SLE CD40L interaction with CD40 on B cells is known to exacerbate disease severity by promoting autoantibody production. Exploring anti-CD40L therapeutic strategies can offer potential intervention in such diseases.